Korean Journal of Radiology

  • 제19권2호
  • /
  • Pages.237-246
  • /
  • 2018
  • /
  • 1229-6929(pISSN)
  • /
  • 2005-8330(eISSN)
대한영상의학회 (The Korean Society of Radiology)
권호 표지
DOI QR코드

DOI QR Code

Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas

  • Zheng, Lin (Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University) ;
  • Li, Hai-Liang (Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University) ;
  • Guo, Chen-Yang (Department of Minimal-Invasive Intervention, The Affiliated Cancer Hospital of Zhengzhou University) ;
  • Luo, Su-Xia (Department of Medical Gastroenterology, The Affiliated Cancer Hospital of Zhengzhou University)
  • 투고 : 2017.07.04
  • 심사 : 2017.08.28
  • 발행 : 2018.04.01
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To evaluate the efficacy and prognostic factors associated with transcatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA) versus TACE alone for a large solitary or multinodular hepatocellular carcinomas (HCCs). Materials and Methods: This retrospective study involved 258 patients with a large solitary or multinodular HCCs (not more than 10 tumors) who underwent TACE + MWA (n = 92) or TACE alone (n = 166) between July 2011 and April 2015. Local tumor control, survival outcomes, and complications were compared between the two groups. Prognostic factors for time to progression (TTP) and overall survival (OS) were evaluated by univariate and multivariate analyses. Results: The median duration of follow-up was 21.2 months (range, 4-45 months). The median TTP and OS were 12.5 months and 26.6 months, respectively, for the TACE + MWA group and 6.7 months and 17.1 months, respectively, for the TACE group (p < 0.001). The 1-, 2-, and 3-year OS rates were 85.9, 59.8, and 32.6%, respectively, for the TACE + MWA group and 59.0, 40.4, and 11.4%, respectively, for the TACE group (p < 0.001). The corresponding recurrence rates were 47.8, 78.3, and 94.6% for the TACE + MWA group, respectively, and 74.7, 96.4, and 97.6%, respectively, for the TACE group (p < 0.001). Logistic regression analyses showed that the treatment method, tumor size, and tumor number were significant prognostic factors for TTP and OS. Conclusion: TACE + MWA appears to have more advantages compared to TACE in prolonging OS, with a satisfactory TTP, for inpatients with solitary large or multinodular HCCs. Treatment method, tumor size, and tumor number are significant prognostic factors for TTP and OS. Further randomized, multi-center, prospective trials are required to confirm the findings of this study.

키워드

참고문헌

  1. Kishore S, Friedman T, Madoff DC. Update on embolization therapies for hepatocellular carcinoma. Curr Oncol Rep 2017;19:40 https://doi.org/10.1007/s11912-017-0597-2
  2. Jung YK, Jung CH, Seo YS, Kim JH, Kim TH, Yoo YJ, et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A. J Gastroenterol Hepatol 2016;31:467-474 https://doi.org/10.1111/jgh.13152
  3. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711 https://doi.org/10.1093/jnci/djn134
  4. Wang YX, De Baere T, Idee JM, Ballet S. Transcatheter embolization therapy in liver cancer: an update of clinical evidences. Chin J Cancer Res 2015;27:96-121
  5. Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol 2012;39:503-509 https://doi.org/10.1053/j.seminoncol.2012.05.004
  6. Farinati F, Giacomin A, Vanin V, Giannini E, Trevisani F. TACE treatment in hepatocellular carcinoma: what should we do now? J Hepatol 2012;57:221-222 https://doi.org/10.1016/j.jhep.2011.12.022
  7. Choi TW, Kim HC, Lee JH, Yu SJ, Kang B, Hur S, et al. The safety and clinical outcomes of chemoembolization in childpugh class C patients with hepatocellular carcinomas. Korean J Radiol 2015;16:1283-1293 https://doi.org/10.3348/kjr.2015.16.6.1283
  8. Liu PH, Hsu CY, Lee YH, Hsia CY, Huang YH, Su CW, et al. When to perform surgical resection or radiofrequency ablation for early hepatocellular carcinoma?: a nomogram-guided treatment strategy. Medicine (Baltimore) 2015;94:e1808 https://doi.org/10.1097/MD.0000000000001808
  9. Wang X, Hu Y, Ren M, Lu X, Lu G, He S. Efficacy and safety of radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinomas compared with radiofrequency ablation alone: a time-to-event metaanalysis. Korean J Radiol 2016;17:93-102 https://doi.org/10.3348/kjr.2016.17.1.93
  10. Bertrand J, Caillol F, Borentain P, Raoul JL, Heyries L, Bories E, et al. Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients. Hepat Med 2015;7:21-27
  11. Abdelaziz AO, Abdelmaksoud AH, Nabeel MM, Shousha HI, Cordie AA, Mahmoud ShH, et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 2017;18:189-194
  12. Xu Y, Shen Q, Wang N, Liu P, Wu P, Peng Z, et al. Percutaneous microwave ablation of 5-6 cm unresectable hepatocellular carcinoma: local efficacy and long-term outcomes. Int J Hyperthermia 2017;33:247-254 https://doi.org/10.1080/02656736.2016.1239842
  13. Si ZM, Wang GZ, Qian S, Qu XD, Yan ZP, Liu R, et al. Combination therapies in the management of large (${\geq}$ 5 cm) hepatocellular carcinoma: microwave ablation immediately followed by transarterial chemoembolization. J Vasc Interv Radiol 2016;27:1577-1583 https://doi.org/10.1016/j.jvir.2016.02.014
  14. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022 https://doi.org/10.1002/hep.24199
  15. Choe WH, Kim YJ, Park HS, Park SW, Kim JH, Kwon SY. Short-term interval combined chemoembolization and radiofrequency ablation for hepatocellular carcinoma. World J Gastroenterol 2014;20:12588-12594 https://doi.org/10.3748/wjg.v20.i35.12588
  16. Kang HJ, Kim YI, Kim HC, Jae HJ, Hur S, Chung JW. Does establishing a safety margin reduce local recurrence in subsegmental transarterial chemoembolization for small nodular hepatocellular carcinomas? Korean J Radiol 2015;16:1068-1078 https://doi.org/10.3348/kjr.2015.16.5.1068
  17. Lee EW, Alanis L, Cho SK, Saab S. Yttrium-90 selective internal radiation therapy with glass microspheres for hepatocellular carcinoma: current and updated literature review. Korean J Radiol 2016;17:472-488 https://doi.org/10.3348/kjr.2016.17.4.472
  18. Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, et al. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol 2017;66:1166-1172 https://doi.org/10.1016/j.jhep.2017.01.012
  19. Zhu ZX, Liao MH, Wang XX, Huang JW. Transcatheter arterial chemoembolization plus 131i-labelled metuximab versus transcatheter arterial chemoembolization alone in intermediate/advanced stage hepatocellular carcinoma: a systematic review and meta-analysis. Korean J Radiol 2016;17:882-892 https://doi.org/10.3348/kjr.2016.17.6.882
  20. Lahat E, Eshkenazy R, Zendel A, Zakai BB, Maor M, Dreznik Y, et al. Complications after percutaneous ablation of liver tumors: a systematic review. Hepatobiliary Surg Nutr 2014;3:317-323
  21. Schneeweis S, Horger M, Ketelsen D, Ioanoviciu SD. [Complications after TACE in HCC - complications after transarterial chemoembolization (TACE) in hepatocellular carcinoma]. Rofo 2015;187:79-82 https://doi.org/10.1055/s-0034-1369532
  22. Schlachterman A, Craft WW Jr, Hilgenfeldt E, Mitra A, Cabrera R. Current and future treatments for hepatocellular carcinoma. World J Gastroenterol 2015;21:8478-8491 https://doi.org/10.3748/wjg.v21.i28.8478
  23. Massani M, Stecca T, Ruffolo C, Bassi N. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg 2017;69:67-73 https://doi.org/10.1007/s13304-017-0414-3
  24. Liu YS, Ou MC, Tsai YS, Lin XZ, Wang CK, Tsai HM, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicinloaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol 2015;16:125-132 https://doi.org/10.3348/kjr.2015.16.1.125
  25. Wang W, Shi J, Xie WF. Transarterial chemoembolization in combination with percutaneous ablation therapy in unresectable hepatocellular carcinoma: a meta-analysis. Liver Int 2010;30:741-749 https://doi.org/10.1111/j.1478-3231.2010.02221.x
  26. Zhao M, Wang JP, Pan CC, Li W, Huang ZL, Zhang L, et al. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012;81:2717-2725 https://doi.org/10.1016/j.ejrad.2011.10.023
  27. Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol 2013;28:456-463 https://doi.org/10.1111/jgh.12088
  28. Lucchina N, Tsetis D, Ierardi AM, Giorlando F, Macchi E, Kehagias E, et al. Current role of microwave ablation in the treatment of small hepatocellular carcinomas. Ann Gastroenterol 2016;29:460-465
  29. Fong ZV, Palazzo F, Needleman L, Brown DB, Eschelman DJ, Chojnacki KA, et al. Combined hepatic arterial embolization and hepatic ablation for unresectable colorectal metastases to the liver. Am Surg 2012;78:1243-1248
  30. Ni JY, Sun HL, Chen YT, Luo JH, Chen D, Jiang XY, et al. Prognostic factors for survival after transarterial chemoembolization combined with microwave ablation for hepatocellular carcinoma. World J Gastroenterol 2014;20:17483-17490 https://doi.org/10.3748/wjg.v20.i46.17483
  31. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol 2012;81:e189-e193 https://doi.org/10.1016/j.ejrad.2011.01.122
  32. Sun AX, Cheng ZL, Wu PP, Sheng YH, Qu XJ, Lu W, et al. Clinical outcome of medium-sized hepatocellular carcinoma treated with microwave ablation. World J Gastroenterol 2015;21:2997-3004 https://doi.org/10.3748/wjg.v21.i10.2997
  33. Salvalaggio PR, Felga GE, Alves JA, Meirelles RF Jr, Almeida MD, de Rezende MB. Response to transarterial chemoembolization in candidates with hepatocellular carcinoma within Milan criteria does not predict post-transplant disease-free survival. Transplant Proc 2014;46:1799-1802 https://doi.org/10.1016/j.transproceed.2014.05.039
  34. Yin X, Zhang L, Wang YH, Zhang BH, Gan YH, Ge NL, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer 2014;14:849 https://doi.org/10.1186/1471-2407-14-849
  35. Jin YJ, Lee JW. Therapeutic priorities for solitary large hepatocellular carcinoma in a hepatitis B virus endemic area; an analysis of a nationwide cancer registry database. J Surg Oncol 2017;115:407-416 https://doi.org/10.1002/jso.24519
  36. Kawaguchi T, Ohkawa K, Imanaka K, Tamai C, Kawada N, Ikezawa K, et al. Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients. Hepatogastroenterology 2012;59:219-223
  37. Leung U, Kuk D, D'Angelica MI, Kingham TP, Allen PJ, DeMatteo RP, et al. Long-term outcomes following microwave ablation for liver malignancies. Br J Surg 2015;102:85-91 https://doi.org/10.1002/bjs.9649
  38. Jianyong L, Lunan Y, Wentao W, Yong Z, Bo L, Tianfu W, et al. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection? Medicine (Baltimore) 2014;93:e180 https://doi.org/10.1097/MD.0000000000000180
  39. Liu PH, Su CW, Hsu CY, Hsia CY, Lee YH, Huang YH, et al. Solitary large hepatocellular carcinoma: staging and treatment strategy. PLoS One 2016;11:e0155588 https://doi.org/10.1371/journal.pone.0155588
  40. Kim JH, Shim JH, Lee HC, Sung KB, Ko HK, Ko GY, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int 2017;37:1861-1868 https://doi.org/10.1111/liv.13487
  41. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013;31:426-432
  42. Yamakado K, Miyayama S, Hirota S, Mizunuma K, Nakamura K, Inaba Y, et al. Subgrouping of intermediate-stage (BCLC stage B) hepatocellular carcinoma based on tumor number and size and Child-Pugh grade correlated with prognosis after transarterial chemoembolization. Jpn J Radiol 2014;32:260-265 https://doi.org/10.1007/s11604-014-0298-9
  43. Zhong JH, Rodríguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 2015;94:e396 https://doi.org/10.1097/MD.0000000000000396
  44. Dong ZR, Zhang PF, Wang CH, Zhang C, Cai JB, Shi GM, et al. Postoperative adjuvant transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond the Milan criteria: a retrospective analysis. Am J Cancer Res 2014;5:450-457

피인용 문헌

  1. Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma vol.53, pp.12, 2018, https://doi.org/10.1080/00365521.2018.1548645
  2. A Glimpse on Trends and Characteristics of Recent Articles Published in the Korean Journal of Radiology vol.20, pp.12, 2019, https://doi.org/10.3348/kjr.2019.0928
  3. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial che vol.36, pp.1, 2019, https://doi.org/10.1080/02656736.2019.1646927
  4. The efficacy of transarterial chemoembolization combined with microwave ablation for unresectable hepatocellular carcinoma: a systematic review and meta-analysis vol.36, pp.1, 2019, https://doi.org/10.1080/02656736.2019.1692148
  5. The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma vol.2019, pp.None, 2019, https://doi.org/10.1155/2019/8619096
  6. Clinical conditions and treatment requirements for long‐term survival among hepatitis B‐related hepatocellular carcinoma initially treated with chemoembolization vol.8, pp.11, 2018, https://doi.org/10.1002/cam4.2380
  7. Transcatheter arterial chemoembolization combined with microwave ablation for treatment of early liver cancer: Efficacy and prognostic factors for progression-free survival vol.27, pp.19, 2019, https://doi.org/10.11569/wcjd.v27.i19.1201
  8. Characteristics of Recent Articles Published in the Korean Journal of Radiology Based on the Citation Frequency vol.21, pp.12, 2020, https://doi.org/10.3348/kjr.2020.1322
  9. Unresectable Hepatocellular Carcinoma: Transcatheter Arterial Chemoembolization Combined With Microwave Ablation vs. Combined With Cryoablation vol.10, pp.None, 2020, https://doi.org/10.3389/fonc.2020.01285
  10. Microwave ablation versus sorafenib for intermediate-Stage Hepatocellular carcinoma with transcatheter arterial chemoembolization refractoriness: a propensity score matching analysis vol.37, pp.1, 2018, https://doi.org/10.1080/02656736.2020.1752400
  11. Diagnosis, Staging, and Patient Selection for Locoregional Therapy to Treat Hepatocellular Carcinoma vol.37, pp.5, 2018, https://doi.org/10.1055/s-0040-1719185
  12. Combined therapy with conventional trans-arterial chemoembolization (cTACE) and microwave ablation (MWA) for hepatocellular carcinoma &gt;3-&lt;5 cm vol.38, pp.1, 2018, https://doi.org/10.1080/02656736.2021.1887941
  13. Hyperthermia ablation combined with transarterial chemoembolization versus monotherapy for hepatocellular carcinoma: A systematic review and meta‐analysis vol.10, pp.23, 2021, https://doi.org/10.1002/cam4.4350
  14. Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines? vol.13, pp.12, 2018, https://doi.org/10.4251/wjgo.v13.i12.1896